How to Localize Labels and Instructions for Overseas Registration of Sterile Consumables?

Localization of labels and instructions for overseas registration of sterile consumables is not a simple translation task but an integral part of regulatory compliance. Manufacturers should first determine whether the product falls within the scope of medical device regulation in the target country, then confirm the regulatory pathway and applicant based on product classification. The content of labels and instructions must satisfy local regulatory and language requirements and remain consistent with the technical documentation. Key items include intended use, contraindications, sterilization method, shelf life, storage conditions, manufacturer information and local representative details. Manufacturers need to prepare source-country labels, risk management documentation, performance verification data, and clinical evaluation or evidence, and assess whether existing documentation such as NMPA, CE, FDA, ISO 13485, or MDSAP can be reused. Common risks include inaccurate translation, inconsistency between terminology and registration files, unclear responsibilities of the local representative, absence of change control, and delayed post-market label updates. A structured localization workflow should be established to verify each item against the target country's regulatory checklist and ensure closed-loop consistency among the registration certificate, labels, instructions and post-market information.

Applicable Scenarios and Core Issues

In overseas registration of sterile consumables, the localization of labels and instructions is often treated as a translation task, but it is actually a critical part of the registration evidence chain. During review, the target country's regulatory authority will compare the labels and instructions with the product technical documentation, performance verification results, risk management report, and clinical evaluation conclusions. Any inconsistency may lead to a deficiency response or rejection.

Applicable scenarios include registrations in GHWP member countries, Southeast Asian countries, Middle East and Latin American market access, and simultaneous submissions in multiple countries. Manufacturers face different languages, different regulatory systems, and different label review requirements. Localization is no longer a document conversion exercise but a matter of regulatory implementation.

The core questions are: Does the manufacturer understand the specific label and instruction requirements of the target country? Is there a localized label template that is consistent with the registration technical documentation? And is there a mechanism for continuous updates?

Registration Determination Logic

Step 1: Determine regulatory scope. Assess whether the product falls under the target country's medical device regulatory scope. Definitions, classifications, and regulatory boundaries for sterile consumables vary by country.

Step 2: Determine risk classification. Sterile consumables may be classified as low, medium, or high risk. The classification determines the registration pathway, review depth, and label requirements. Do not simply adopt the classification from the country of origin; instead, re-evaluate according to the target country's classification rules.

Step 3: Determine the applicant or local entity. Most countries require a local registrant or local agent. Manufacturers must clarify the division of responsibilities between the manufacturer and the local agent, particularly the local agent information that must appear on the label.

Step 4: Evaluate reuse of existing documentation. Inventory NMPA registration files, CE technical documentation, FDA 510(k) or PMA submissions, ISO 13485 quality system documentation, and MDSAP audit reports. Determine which documents can serve as technical evidence and which must be converted into the target country's format, especially clinical claims, terminology, and format requirements for labels and instructions.

Step 5: Confirm post-market maintenance requirements. Labels and instructions are not static after approval. Any changes must be evaluated to determine whether notification or a change application is required. The change management process should be planned during the registration phase.

Documentation and Evidence

The materials required for label and instruction localization are not limited to the original label and translation draft; they form a complete evidence chain.

• Product technical documentation: Includes product description, material composition, sterilization method, performance specifications, shelf-life validation, and packaging integrity validation. Every technical parameter on the label must have a basis in the technical file.
• Risk management documentation: Cautions, contraindications, and warning statements on labels and instructions must derive from the risk control measures in the risk management report. These statements cannot be arbitrarily rewording during localization.
• Clinical evaluation or evidence: If the instructions make claims about clinical efficacy, indications, or performance, corresponding clinical data must be provided. Without clinical evidence, related claims may be deleted or additional clinical work may be required.
• Country-of-origin registration certificate and label approval documents: Some countries recognize the origin-country registration as a basis but require notarized or authenticated proof of registration.
• Quality system certificates: Such as ISO 13485 or MDSAP certificates. These prove stable production capability and continuous compliance; the manufacturing address and manufacturer information on the label must match the certificates.
• Local agent agreement and authorization letter: Labels and instructions typically require the name and address of the local agent or authorized representative. Valid authorization documents must be prepared.

Common Errors

• Directly translating the English or Chinese label into the target language without adjusting mandatory labeling requirements for local regulations.
• Inconsistency between the product name, model/specification, and intended use on the label and those in the technical documentation, raising questions during review.
• Ignoring local language requirements—for example, some countries require the national language, or allow multiple languages but mandate one national language.
• Failing to list the local agent or authorized representative, or listing information that differs from the valid authorization document.
• Confusing sterile and non-sterile labeling conventions, inconsistent with the sterilization validation report.
• Errors in numerical units for shelf life and storage conditions after translation, such as temperature or humidity units not converted.
• Missing warning statements from the risk management report on the label, which regulators may deem insufficient risk control.
• No post-approval label change control procedure, leading to inconsistencies between the approved label and the actual marketed label.

Manufacturer Preparation Checklist

• Establish a regulatory checklist for the target country, listing all mandatory content requirements for labels and instructions.
• Determine product classification and registration pathway; create a localization compliance plan.
• Inventory existing technical documents, registration certificates, and quality system certificates; identify reusable files and files that need to be rewritten.
• Develop a terminology list for labels and instructions to ensure consistent use of terms across technical files, registration submissions, and labels.
• Designate a local agent or authorized representative and prepare the authorization agreement, address proof, and contact details.
• Complete language translation and regulatory review of labels and instructions; the final confirmation should preferably be done by a local regulatory advisor or the local agent.
• Perform consistency checks between label content, technical files, and risk management documents.
• Establish a post-market label change management process, defining responsible persons and timelines for change evaluation, notification, and filing or change applications.
• Prepare modular label templates for multi-country registration to facilitate additions or deletions based on each country's requirements.

Common Follow-up Questions

Is it necessary to translate labels and instructions into the official language of the target country?

Most countries require the official language, while some accept English. Manufacturers should check the medical device regulations or guidelines of the target country. Even if English is accepted, certain mandatory items may still need to be in the local language. A prudent approach is to prepare the official-language version and have it confirmed by the local agent.

Can the country-of-origin label be used directly for overseas registration?

Generally no. The country-of-origin label may lack the local agent information, warning statements, unit system, or special markings required by the target country. Even if content is similar, localization adjustments are necessary and the label must be consistent with the target country's registration files.

Do changes to labels and instructions require re-registration?

It depends on the nature of the change. Minor changes, such as an address update, may only require notification to the regulatory authority. Substantive changes involving intended use, technical parameters, or warnings may require a change application, and in some cases re-registration. Manufacturers should establish a change evaluation process.

Can a unified label version be used for multi-country registration?

A unified template is possible, but a single identical version is not. Different countries have different language, regulatory, and local representative requirements. A modular template is recommended, with basic information and technical parameters as the common section and country-specific information as differentiated modules. This improves efficiency.

AIMEILI Regulatory Interpretation and Business Impact

In overseas registration of sterile consumables, the most common misjudgment is treating label and instruction localization as a document translation project rather than a regulatory compliance task. Many deficiency responses arise because technical parameters on the label are inconsistent with the technical files, or risk management statements are missing.

At the beginning of a project, manufacturers should first conduct a gap analysis of the target country's compliance requirements and avoid rushing into translation. The local regulations, standards, guidelines, and review priorities must be studied thoroughly to identify mandatory label information, recommended content, and content that is not allowed.

Reusable documents mainly include product technical data, performance verification reports, quality management system evidence, and origin-country registration information. Elements that must be localized include language, units, regulatory warning statements, local representative information, classification markings, and certain special marking requirements of specific countries.

Control of the local representative and certificate is critical. Labels and instructions often must show local representative information; if a representative change is not reflected promptly, customs clearance and market launch can be affected. Similarly, manufacturers should not delegate full control of the registration certificate to an agent, as subsequent changes, renewals, and label adjustments may become unmanageable.

For multi-country registration, a modular document strategy should be adopted. The core technical documentation remains unchanged, while the localization layer adjusts labels and instructions according to each country's requirements. This reduces duplication and deficiency risks, and avoids preparing an entire dossier for each country. We recommend that manufacturers involve the local agent in label review at an early stage rather than waiting for questions after submission.

Business impact: Delayed or inaccurate label localization can lead to regulatory delays, additional costs, product launch setbacks, and loss of market opportunities. A robust localization process and early involvement of local advisors can significantly shorten approval timelines, reduce the risk of deficiency responses, and ensure smoother multi-market entry.

Content Review and Applicability

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI International Medical Device Registration Project Group. Source principle: Priority is given to official regulatory authorities, international organizations, standard organizations, and publicly available regulatory materials; industry media and project experience are used only as supporting references. This article is compiled based on AIMEILI's registration practice knowledge base and publicly available regulatory information; specific projects should follow the latest requirements of the target country's regulatory authority and the actual product documentation.

Applicability: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal opinions.